Why Is Recursion Pharmaceuticals (RXRX) Stock Down -8.89% Today?
Key Takeaways
- RXRX shares fell about 8.9% to roughly $3.79, giving back much of the previous session's sharp gains.
- The decline followed an 11.2% surge on October 15, the stock's best single-day performance in more than a year.
- A newly priced $200 million follow-on stock offering, sold at $3.25 per share, is fueling dilution concerns and profit-taking.
- The pullback comes after Sanofi selected the first drug candidate under its AI-enabled collaboration, triggering a $10 million milestone payment.
- Traders are watching third-quarter results expected in early November and further pipeline and partnership updates.
Opening Summary
Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage "TechBio" company that uses an AI-driven platform called the Recursion OS to industrialize drug discovery, saw its shares pull back sharply on Thursday. After closing the prior session at $4.16, the stock traded down roughly 8.9% to about $3.79 in early trading, reversing a meaningful portion of the previous day's rally. The move reflects a combination of profit-taking after a one-day surge and investor unease over the dilutive stock offering the company priced a day earlier.
Follow-On Offering Weighs on Shares
The most direct headwind facing RXRX is a newly announced $200 million underwritten offering of 61.54 million shares of Class A common stock, priced at $3.25 per share. That price represented a discount of roughly 13% to the stock's closing level before the deal was unveiled, and the expanded share count is expected to weigh on existing holders as the new shares enter the market. The offering, which the company said was oversubscribed, is intended to extend its cash runway into 2029, but the near-term dilution and the discounted pricing gave traders an incentive to lock in gains from the prior session's spike.
Profit-Taking After the Sanofi-Fueled Surge
The decline is also a classic give-back move following an outsized one-day advance. On October 15, RXRX surged more than 11% after Sanofi exercised an option on the first development candidate to emerge from the companies' multi-program collaboration, an oral small molecule targeting a dual mechanism in inflammatory disease. The milestone triggered a $10 million payment, bringing cumulative upfront and milestone payments from Sanofi to $144 million, with more than $300 million in additional milestones and double-digit royalties potentially available. Positive clinical updates for the REC-4881 and REC-1245 programs reinforced the bullish narrative. With those gains largely intact entering Thursday's session, some investors chose to sell into strength.
Market Context and Trading Activity
Trading volume was unusually heavy across the two sessions, with well over 60 million shares changing hands during Wednesday's rally compared with a 20-day average closer to 20 million. Thursday's decline unfolded on continued elevated turnover as the dilution overhang and a heavily shorted share base amplified volatility. RXRX has significant short interest relative to its float, a condition that can magnify moves in both directions as positions are covered or added. The stock remains above its 50-day and 200-day moving averages, and it had risen roughly 28% over the prior month, leaving it vulnerable to a near-term pullback even in the absence of negative company-specific news.
What Comes Next for RXRX
Looking ahead, investors will focus on RXRX's third-quarter earnings report, expected in early November, which will provide updated detail on the company's cash position and the timing of the recently completed offering. Additional Sanofi collaboration milestones, progress toward a Phase 1 start for the newly optioned inflammatory-disease candidate in 2027, and further data from the REC-4881 and REC-1245 programs are among the key catalysts that could shape sentiment. At the same time, the company's ongoing cash burn and reliance on equity financing remain central risks, and any clinical or regulatory setback could renew pressure on the shares.
Trending AI Robots
Traders seeking a more systematic approach to opportunities like this can explore Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a range of tools to suit different approaches. Visit Trending AI Robots to review the latest top performers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
RXRX sees MACD Histogram just turned negative
RXRX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 51 instances where the indicator turned negative. In 48 of the 51 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RXRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on RXRX as a result. In 83 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
RXRX moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 206 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 105 of 131 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.169) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement